19 July 2023
19 July 2023
Numerous factors have led to a decline in the number of clinical trials in the UK, even with significant investment in life sciences.
BeiGene tops other pharmaceutical companies over the second quarter of 2023, clinching high financial earnings.
The updates include Phase II trial enrolment and interim safety data, with plans to begin Phase III trials in 2024.
The combined solution pulls data from various sources, including participant and clinician-reported data provided by Thread.
The Phase I trial evaluates the combination Telix’s targeted radiation therapy with Merck’s peposertib, a DNA-PK Inhibitor.
ENX-102 is an investigational, subtype-selective GABA-A positive allosteric modulator.
Patients with decompensated cirrhosis experience complications including hepatic encephalopathy and ascites.
Topline results from the study are anticipated in the first quarter of next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
